Renaissance Technologies - FREELINE THERAPEUTICS HLDGS ownership

FREELINE THERAPEUTICS HLDGS's ticker is FRLN and the CUSIP is 35655L107. A total of 1 filers reported holding FREELINE THERAPEUTICS HLDGS in Q2 2023. The put-call ratio across all filers is - and the average weighting 5.7%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of FREELINE THERAPEUTICS HLDGS
ValueSharesWeighting
Q1 2023$105
+12.9%
230,600
+17.4%
0.00%
Q4 2022$93
-99.9%
196,390
-8.2%
0.00%
Q3 2022$150,000
-35.1%
214,000
-19.3%
0.00%
Q2 2022$231,000
-53.8%
265,223
-40.6%
0.00%
-100.0%
Q1 2022$500,000
+20.2%
446,412
+112.5%
0.00%0.0%
Q4 2021$416,000
-37.3%
210,100
+8.0%
0.00%0.0%
Q3 2021$663,000194,5000.00%
Other shareholders
FREELINE THERAPEUTICS HLDGS shareholders Q2 2023
NameSharesValueWeighting ↓
CHI Advisors LLC 1,379,843$11,246,0002.62%
Novo Holdings A/S 2,361,229$19,244,0000.85%
Ally Bridge Group (NY) LLC 401,747$3,274,0000.81%
SECTORAL ASSET MANAGEMENT INC 640,714$5,222,0000.42%
FRAZIER MANAGEMENT LLC 550,000$4,483,0000.41%
TFG Asset Management GP Ltd 750,000$6,113,0000.33%
Eventide Asset Management 2,485,656$19,757,0000.26%
AXA S.A. 1,111,510$9,058,0000.01%
Woodline Partners LP 25,932$211,0000.00%
WELLINGTON MANAGEMENT GROUP LLP 2,001,951$16,315,0000.00%
View complete list of FREELINE THERAPEUTICS HLDGS shareholders